Kyntra Bio, Inc. (KYNB)
| Market Cap | 28.53M |
| Revenue (ttm) | 6.44M |
| Net Income (ttm) | 183.45M |
| Shares Out | 4.05M |
| EPS (ttm) | 45.38 |
| PE Ratio | 0.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,411 |
| Open | 7.05 |
| Previous Close | 7.03 |
| Day's Range | 7.05 - 7.21 |
| 52-Week Range | 4.85 - 12.60 |
| Beta | 0.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2026 |
About KYNB
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ... [Read more]
Financial Performance
Financial StatementsNews
Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its business, repaid debt, and now focuses on advancing its ADC FG-3246 and PET imaging agent FG-3180 in mCRPC, with interim Phase II data expected in H2 2024. Roxadustat is being prepared for a Phase III trial in lower-risk MDS, with funding or partnership options under evaluation.
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-1...
Kyntra Bio Earnings Call Transcript: Q4 2025
2025 marked a transformational year with the sale of FibroGen China, debt repayment, and rebranding, extending cash runway into 2028. FG-3246 and FG-3180 advanced in mCRPC with promising early data, while roxadustat progressed in MDS with orphan drug status and a phase III trial planned for late 2026.
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and rema...
Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026
Kyntra Bio highlighted its transformation, extended cash runway, and focus on two lead assets: FG-3246/FG-3180 for prostate cancer and Roxadustat for lower risk MDS. Key clinical trials are underway, with interim results for prostate cancer expected in H2 2024 and a new phase III MDS trial pending FDA feedback.
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 aft...
Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Kyntra Bio, following its rebranding and strategic refocus, is advancing a novel CD46-targeting ADC and companion PET imaging agent in mCRPC, with interim phase II results expected this year. Roxadustat is poised for phase III in MDS, supported by FDA alignment and orphan drug status.
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide fo...
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalu...
Kyntra Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company's management will participate in the following investor c...
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Comp...
Kyntra Bio Earnings Call Transcript: Q3 2025
Q3 2025 saw a transformative $220M China sale, major cost reductions, and a cash runway into 2028. FG-3246 and Roxadustat clinical programs advanced, with key trial milestones expected in 2026. Roxadustat phase III trial funding may require additional capital or a partner.
FibroGen to Report Third Quarter 2025 Financial Results
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct ...
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-clas...
Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A transformative sale of China operations has extended the cash runway into 2028 and eliminated debt. The pipeline features a novel ADC for prostate cancer with promising early results and a phase 2 trial starting soon, while roxadustat advances toward a phase 3 trial in lower risk MDS.
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Co...
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Ho...
Kyntra Bio Earnings Call Transcript: Q2 2025
Q2 2025 saw a transformative China sale boosting cash runway into 2028, significant cost reductions, and progress on FG-3246 and roxadustat clinical programs. Phase II and III trials are on track, with strong financial positioning and multiple near-term catalysts.
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments.
FibroGen to Report Second Quarter 2025 Financial Results
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also cond...
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.
FibroGen Announces 1-for-25 Reverse Stock Split
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Revers...
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
Kyntra Bio Earnings Call Transcript: Q1 2025
Divestiture of China operations for $185M boosts cash runway into H2 2027 and enables payoff of debt. Focus shifts to U.S. pipeline, with phase II trials for FG-3246/FG-3180 in MCRPC and regulatory progress for roxadustat in MDS. Q1 2025 saw reduced losses and positive cash flow.
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.